Show simple item record

dc.contributor.author Person, AK
dc.contributor.author Goswami, ND
dc.contributor.author Bissette, DJ
dc.contributor.author Turner, DS
dc.contributor.author Baker, AV
dc.contributor.author Gadkowski, LB
dc.contributor.author Naggie, S
dc.contributor.author Erlandson, K
dc.contributor.author Chen, L
dc.contributor.author Lalani, T
dc.contributor.author Cox, GM
dc.contributor.author Stout, JE
dc.coverage.spatial United States
dc.date.accessioned 2011-04-15T16:46:21Z
dc.date.issued 2010-09
dc.identifier http://www.ncbi.nlm.nih.gov/pubmed/20731612
dc.identifier.citation AIDS Patient Care STDS, 2010, 24 (9), pp. 539 - 543
dc.identifier.uri http://hdl.handle.net/10161/3350
dc.description.abstract Knowing one's HIV status is particularly important in the setting of recent tuberculosis (TB) exposure. Blood tests for assessment of tuberculosis infection, such as the QuantiFERON Gold in-tube test (QFT; Cellestis Limited, Carnegie, Victoria, Australia), offer the possibility of simultaneous screening for TB and HIV with a single blood draw. We performed a cross-sectional analysis of all contacts to a highly infectious TB case in a large meatpacking factory. Twenty-two percent were foreign-born and 73% were black. Contacts were tested with both tuberculin skin testing (TST) and QFT. HIV testing was offered on an opt-out basis. Persons with TST >or=10 mm, positive QFT, and/or positive HIV test were offered latent TB treatment. Three hundred twenty-six contacts were screened: TST results were available for 266 people and an additional 24 reported a prior positive TST for a total of 290 persons with any TST result (89.0%). Adequate QFT specimens were obtained for 312 (95.7%) of persons. Thirty-two persons had QFT results but did not return for TST reading. Twenty-two percent met the criteria for latent TB infection. Eighty-eight percent accepted HIV testing. Two (0.7%) were HIV seropositive; both individuals were already aware of their HIV status, but one had stopped care a year previously. None of the HIV-seropositive persons had latent TB, but all were offered latent TB treatment per standard guidelines. This demonstrates that opt-out HIV testing combined with QFT in a large TB contact investigation was feasible and useful. HIV testing was also widely accepted. Pairing QFT with opt-out HIV testing should be strongly considered when possible.
dc.format.extent 539 - 543
dc.language ENG
dc.language.iso en_US en_US
dc.relation.ispartof AIDS Patient Care STDS
dc.relation.isversionof 10.1089/apc.2010.0102
dc.subject Adult
dc.subject Aged
dc.subject Contact Tracing
dc.subject Cross-Sectional Studies
dc.subject Female
dc.subject HIV Antibodies
dc.subject HIV Infections
dc.subject Humans
dc.subject Interferon-gamma
dc.subject Male
dc.subject Middle Aged
dc.subject Mycobacterium tuberculosis
dc.subject Retrospective Studies
dc.subject Southeastern United States
dc.subject Tuberculin Test
dc.subject Tuberculosis, Pulmonary
dc.subject Viral Load
dc.subject Young Adult
dc.title Pairing QuantiFERON gold in-tube with opt-out HIV testing in a tuberculosis contact investigation in the Southeastern United States.
dc.type Journal Article
dc.description.version Version of Record en_US
duke.date.pubdate 2010-9-0 en_US
duke.description.endpage 543 en_US
duke.description.issue 9 en_US
duke.description.startpage 539 en_US
duke.description.volume 24 en_US
dc.relation.journal AIDS Patient Care and STDs en_US
pubs.author-url http://www.ncbi.nlm.nih.gov/pubmed/20731612
pubs.issue 9
pubs.organisational-group /Duke
pubs.organisational-group /Duke/School of Medicine
pubs.organisational-group /Duke/School of Medicine/Basic Science Departments
pubs.organisational-group /Duke/School of Medicine/Basic Science Departments/Molecular Genetics and Microbiology
pubs.organisational-group /Duke/School of Medicine/Clinical Science Departments
pubs.organisational-group /Duke/School of Medicine/Clinical Science Departments/Medicine
pubs.organisational-group /Duke/School of Medicine/Clinical Science Departments/Medicine/Medicine, Infectious Diseases
pubs.organisational-group /Duke/School of Medicine/Institutes and Centers
pubs.organisational-group /Duke/School of Medicine/Institutes and Centers/Duke Clinical Research Institute
pubs.publication-status Published
pubs.volume 24
dc.identifier.eissn 1557-7449

Files in this item

This item appears in the following Collection(s)

Show simple item record